The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis | Zendy

Li Zhao | Zendy; Jie Gao | Zendy; Sheng Min Zheng | Zendy; Yang Wang | Zendy; Xiao Xiang | Zendy; Qian Cheng | Zendy; Jiye Zhu | Zendy

Open Access

The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis

Author(s) -

Li Zhao,

Jie Gao,

Sheng Min Zheng,

Yang Wang,

Xiao Xiang,

Qian Cheng,

Jiye Zhu

Publication year - 2020

Publication title -

revista española de enfermedades digestivas

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.331

H-Index - 38

eISSN - 2340-4167

pISSN - 1130-0108

DOI - 10.17235/reed.2020.6458/2019

Subject(s) - sorafenib , hepatocellular carcinoma , meta analysis , medicine , oncology , resection , surgery

hepatocellular carcinoma (HCC) recurrence after liver resection remains a major threat for patients' survival. Sorafenib is recommended as an adjuvant treatment for patients after a liver resection. The objective of this meta-analysis was to estimate the therapeutic value of sorafenib in patients who underwent a HCC resection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research